← Back to headlines
Karyopharm Stock Plummets After Xpovio Fails Endometrial Cancer Trial
Karyopharm Therapeutics' stock fell sharply after its drug Xpovio did not meet its primary endpoint in a Phase 3 clinical trial for advanced endometrial cancer.
30 Jul, 23:38 — 30 Jul, 23:38
Sources
Showing 1 of 1 sources
Related Stories
Lionel Richie Hospitalized in ICU Following St. Louis Concert
1h ago
Anna Hazare admitted to Mumbai hospital's ICU with acute dehydration, kidney issue
9h ago
Ebola Outbreak in Democratic Republic of Congo Surpasses 6,000 Cases
12h ago
England Pharmacies to Offer Free Quick Cholesterol Screening Tests
20h ago